{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000116","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.796888+00:00","generated_at":"2026-05-31T23:44:18.011996+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds","bullets":["Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.","Modification 17 for CYFENDUS anthrax vaccine valued at $30.0M for delivery this year.","Two options totaling $122.9M for VIGIV (smallpox complication) and BAT (botulism antitoxin) into early 2025.","All awards from ASPR under existing 10-year contracts; reaffirms Emergent as trusted biodefense partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000116","json":"https://secwatch.observer/filing/0001367644-24-000116.json","markdown":"https://secwatch.observer/filing/0001367644-24-000116.md","text":"https://secwatch.observer/filing/0001367644-24-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/0001367644-24-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/ebs-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:44:18.011996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}